WO2014204281A9 - 호르몬 분비 조절제, 이를 포함하는 조성물, 및 이를 사용한 호르몬 분비 조절 방법 - Google Patents
호르몬 분비 조절제, 이를 포함하는 조성물, 및 이를 사용한 호르몬 분비 조절 방법 Download PDFInfo
- Publication number
- WO2014204281A9 WO2014204281A9 PCT/KR2014/005508 KR2014005508W WO2014204281A9 WO 2014204281 A9 WO2014204281 A9 WO 2014204281A9 KR 2014005508 W KR2014005508 W KR 2014005508W WO 2014204281 A9 WO2014204281 A9 WO 2014204281A9
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- hormone
- gonadotropin
- pharmaceutical composition
- releasing hormone
- gonadotropin releasing
- Prior art date
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/10—Peptides having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/45—Transferases (2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
- C12N9/1241—Nucleotidyltransferases (2.7.7)
- C12N9/1276—RNA-directed DNA polymerase (2.7.7.49), i.e. reverse transcriptase or telomerase
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
- C12Y207/07—Nucleotidyltransferases (2.7.7)
- C12Y207/07049—RNA-directed DNA polymerase (2.7.7.49), i.e. telomerase or reverse-transcriptase
Definitions
- the present specification provides a hormone secretion modulator comprising a peptide derived from telomerase, specifically, an amino acid sequence of SEQ ID NO: 1, an amino acid sequence having at least 80% sequence homology with SEQ ID NO: 1, or a fragment thereof.
- the present invention also relates to a pharmaceutical composition comprising the hormone secretion regulator and to the use of the pharmaceutical composition for the treatment, amelioration or prevention of a disease caused by excess or deficiency of hormone.
- sex hormones which include testosterone, estrogen, follicle-stimulating hormone (FSH), and luteinizing hormone (LH).
- FSH follicle-stimulating hormone
- LH luteinizing hormone
- GnRH gonadotrophin-releasing hormone
- Testosterone occurs in both men and women and is one of the major sex hormones produced by the body. In men, it is mainly produced in the lydig cells of the testes, and in women it is produced in the ovaries and placenta. It is also common in both sexes. Testosterone, a well known major role, has the property of increasing the mass of secondary muscles, for example, muscle and bone mass and body hair in men.
- Progesterone is a glycoprotein hormone consisting of two subunits. Alpha subunits are similar to those of follicle stimulating hormone, human chorionic gonadotropin (hCG), and thyroid-stimulating hormone (TSH). Beta subunits differ from other glycoprotein hormones and confer biochemical specificity. Progesterone is secreted in response to gonadotropin-releasing hormone released from the anterior pituitary gland and in the hypothalamus in men. Progesterone is also called interstitial-cell-stimulating hormone (ICSH), and luteinizing hormone secretion is positive, including the hypothalamic-pituitary axis, reproductive organs, pituitary gland and sex steroid hormones. And balance of negative feedback mechanism of action. Progesterone and other pituitary gonadotropins and follicle stimulating hormones play an important role in maintaining the normal functioning of the reproductive system in men and women.
- ICSH interstitial-cell-stimulating hormone
- Follicle stimulating hormone is a glycoprotein hormone consisting of two subunits. Alpha subunits are similar to those of progesterone, hCG, TSH. Beta subunits differ from other glycoproteins and confer biochemical specificity. Follicle-stimulating hormone is secreted in the anterior pituitary gland, in response to gonadotropin-releasing hormone secreted from the hypothalamus. In both men and women, the secretion of follicle stimulating hormone is regulated by a balance of positive and negative feedback mechanisms, including the hypothalamic-pituitary axis, reproductive organs, pituitary gland and sex steroid hormones. Follicle-stimulating hormones and luteinizing hormones, other pituitary gonadotropins, and follicle-stimulating hormones play an important role in maintaining the normal functioning of the reproductive system in men and women.
- Estrogens are female steroid hormones, most of which are produced in the ovaries, and a small amount is produced in the adrenal cortex, placenta and male testes. Estrogens help control and guide sexual maturity, including physical changes associated with puberty. It also affects the ovulation cycle in menstruation, lactation period after pregnancy, the direction of feelings, and the aging process. Estrogen production naturally shifts a woman's life cycle, beginning at puberty and reaching adult levels, and decreasing to middle age until just before menopause. Estrogen deficiency can lead to decreased menstruation (menstrual irregularities), persistent menopause-related disorders (eg, mood swings and vaginal dryness), and osteoporosis in old age. In the case of estrogen deficiency, preparations of natural or synthetic estrogens may be prescribed. Estrogen is also one of the components of many oral contraceptives. In men, excess estrogen causes female secondary sexual characteristics (feminization) such as enlargement of breast tissue.
- Gonadotropin releasing hormone is one of a family of peptides that play a central role in reproduction.
- the main function of gonadotropin-releasing hormone is to act on the pituitary gland to stimulate the synthesis and secretion of corpus luteum formation and follicle stimulating hormones, but gonadotropin-releasing hormone is also found in the brain, retina, sympathetic nervous system, gonads, and placenta of certain species.
- Gonadotropin-releasing hormone appears to have at least three different forms. The second form is expressed in the midbrain and appears to be widespread. The third form is rare and is observed only in fish.
- Gonadotropin-releasing hormone is a C-terminal amidated decapeptide derived from a larger precursor protein. Four out of ten residues are perfectly conserved in all species sequenced gonadotropin releasing hormone.
- One aspect of the invention provides a hormone secretion regulator comprising a peptide comprising an amino acid sequence of SEQ ID NO: 1, an amino acid sequence having at least 80% sequence homology with SEQ ID NO: 1, or fragments thereof.
- Another aspect of the present invention provides a pharmaceutical composition for controlling hormone secretion, comprising the hormone secretion modulator according to the present invention.
- Another aspect of the present invention provides the use of the hormone secretion modulator according to the present invention for producing a medicament for controlling hormone secretion.
- Another aspect of the present invention is a pharmaceutical composition according to the present invention.
- kits for controlling hormone secretion including instructions.
- Another aspect of the present invention provides a method for controlling hormone levels, comprising administering an effective amount of a hormone secretion regulator according to the present invention to a subject in need of hormone regulation treatment.
- Another aspect of the present invention provides a method for controlling hormone levels comprising administering an effective amount to the subject in need of hormone regulation treatment, the pharmaceutical composition for controlling hormone secretion according to the present invention.
- Another aspect of the present invention is a gonadotropin-releasing hormone (GnRH) analogue comprising a peptide comprising an amino acid sequence of SEQ ID NO: 1, an amino acid sequence having 80% or more sequence homology with SEQ ID NO: 1, or a fragment thereof To provide.
- GnRH gonadotropin-releasing hormone
- Another aspect of the present invention provides a method for controlling gonadotropin releasing hormone effect comprising administering an effective amount of the gonadotropin releasing hormone analog according to the present invention to a subject in need of hormonal modulating therapy.
- Another aspect of the present invention provides a pharmaceutical composition for controlling gonadotropin releasing hormone effect comprising the gonadotropin releasing hormone analogue according to the present invention.
- Another aspect of the present invention provides the use of the gonadotropin releasing hormone analogue according to the present invention for the manufacture of a medicament for controlling gonadotropin releasing hormone effect.
- the present invention in one aspect,
- a peptide comprising an amino acid sequence of SEQ ID NO: 1, an amino acid sequence having at least 80% sequence homology with SEQ ID NO: 1, or a fragment thereof for controlling hormone secretion is provided.
- Peptides disclosed herein can include peptides having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% homology.
- the peptides disclosed herein, peptides or fragments thereof comprising SEQ ID NO: 1 and one or more amino acids, two or more amino acids, three or more amino acids, four or more amino acids, five or more amino acids, six or more amino acids Or peptides with seven or more amino acids changed.
- homology and sequence identity are used interchangeably, which indicates the degree of overlap of the sequence between two amino acids (or similar nucleic acids).
- sequence homology is calculated using (nref-ndif) * 100 / nref, where the two sequences are aligned to yield the most consensus
- ndif is the total number of non-consistent residues between the two sequences
- nref is the total number of residues of the shorter sequence of the two sequences.
- the amino acid change belongs to a property that allows the physicochemical properties of the peptide to be altered.
- amino acid changes can be made, such as improving the thermal stability of the peptide, altering substrate specificity, changing the optimal pH, and the like.
- the peptide comprising the amino acid sequence of SEQ ID NO: 1, the amino acid sequence having a sequence homology of 80% or more with SEQ ID NO: 1, or fragments thereof according to the present invention has the advantage of low in vivo toxicity and high in vivo safety. .
- SEQ ID NO: 1 EARPALLTSRLRFIPK
- Another aspect of the present invention provides a hormone secretion regulator comprising a peptide comprising an amino acid sequence of SEQ ID NO: 1, an amino acid sequence having 80% or more sequence homology with SEQ ID NO: 1, or a fragment thereof.
- the hormone is sex hormone
- the sex hormone is testosterone (testosterone), estrogen (estrogen), follicle stimulating hormone (FSH, follicle stimulating hormone (FSH), luteinizing hormone (LH, luteinizing hormone), Gonadotropin-releasing hormone (GnRH)
- testosterone testosterone
- estrogen estrogen
- FSH follicle stimulating hormone
- FSH follicle stimulating hormone
- LH luteinizing hormone
- GnRH Gonadotropin-releasing hormone
- the hormone is testosterone.
- Testosterone (4 androsten 17 ⁇ -ol-3-one) is a C19 steroid hormone and is an important androgen for men. It is regulated by the pituitary hormone, the pituitary hormone. Progesterone is secreted from the anterior pituitary gland to control testosterone production and acts directly on the cells of the interstitial tissue of the testes. Testosterone plays a role in stimulating the maturation and secondary character of the external genital organs, in addition to the growth of the face, armpits, and peri-genital (groin) hair.
- Measuring luteinizing hormone and testosterone levels in the circulatory system is useful for identifying gonadotropin decline.
- Low concentrations of testosterone come from reasons such as hypogonadism, testicular insufficiency, high prolactin levels, pituitary gland dysfunction, kidney or liver disease.
- testosterone levels are much lower than in men, and high testosterone levels in women can cause polycystic ovary syndrome and adrenal hyperplasia.
- Excess testosterone may cause infertility, hirsutism, amenorrhea or obesity.
- Testosterone binds very strongly to plasma proteins, such as sex hormone-binding globulin (SHBG) or testosterone-estradiol-binding globulin (TeBG), and weakly to cortisol-binding globulins (CBG) and albumin.
- SHBG sex hormone-binding globulin
- TeBG testosterone-estradiol-binding globulin
- CBG cortisol-binding globulins
- albumin albumin
- the hormone is estrogen
- the estrogen may be estrone (E1), estradiol (E2), or estriol (E3).
- estradiol is the predominant estrogen at the absolute serum level, at estrogen activity, or during reproductive activity. Measurements of estradiol (E2) are used to assess ovarian function and follicles (follicles) in reproductive protocols, such as in vitro fertilization and in medical assistance. It is important for observing maturity. E2 promotes female genital growth, activates secondary sexual characteristics, and plays an essential role in the menstrual cycle. Usually in infertile women, estradiol is mostly secreted during the development of the follicle and corpus luteum by the interaction of the follicle and granule cells.
- estradiol is secreted into the blood, 1-3% is present in the form of no binding to any protein, about 40% is present in the form of binding to SHBG, and the remainder is in the form of binding to albumin.
- the primary function of estradiol is to promote female genital growth and secondary sexual characteristics.
- Estradiol plays an essential role in the female menstrual cycle. In the production start cycle of the antibody, estradiol is maintained at low levels. After about seven days, the maturation of the follicle is controlled by the level of estradiol and the level increases. Increasing estradiol levels cause a spike in luteinizing hormone levels and inhibition of follicle stimulating hormone. Normal ovulation occurs about 10 to 12 hours after the peak of luteinizing hormone (level) and about 24 to 36 hours after the peak of estradiol (level). During the luteal phase, estradiol levels increase and peaks on day 8 after ovulation. This increase in estradiol levels indicates degeneration of the corpus luteum. If fertilization of the fertilized egg does not occur, estradiol decreases and signals the start of the next cycle.
- the estradiol-6 test derives its name from the antigenic antibody reaction at the sixth binding site of E2, the specificity of the test is good, and the test results can be used in various ways.
- the hormone is follicle stimulating hormone.
- the follicle stimulating hormone is a glycoprotein hormone consisting of alpha subunits similar to luteinizing hormone, thyroid stimulating hormone, and human chorionic gonadotropin, and beta subunits that represent the biochemical properties of follicle stimulating hormone. It plays an important role in maintaining normal reproductive function in both men and women. Follicle-stimulating hormone is released from the anterior pituitary gland and is stimulated by gonadotropin-releasing hormone secreted from the hypothalamus. In both men and women, follicle stimulating hormones maintain homeostasis, which is regulated by feedback mechanisms including the hypothalamic-pituitary pathway, reproductive organs, pituitary gland, and sex hormones.
- the site of action and action of follicle stimulating hormone are shown in each male and female as follows.
- follicle stimulating hormone levels indicate menopause and primary gonadotropia in women and are associated with primary gonadotropia in men as well. Reduction of follicle stimulating hormone levels is associated with primary gonadotropin. In women with polycystic follicle syndrome, follicle stimulating hormone levels are normal or decreased.
- said hormone is luteinizing hormone (LH).
- Progesterone is a glycoprotein hormone consisting of two subunits. It consists of an alpha subunit similar to follicle stimulating hormone, thyroid stimulating hormone, and human chorionic gonadotropin, and a beta subunit that exhibits the biochemical properties of luteinizing hormone and differs from other glycoprotein hormones. Progesterone is secreted from the anterior pituitary gland and is stimulated by the secretion of gonadotropin-releasing hormone secreted from the hypothalamus. In men, luteinizing hormone is often called ICSH. In both men and women, luteinizing hormone levels are regulated by feedback mechanisms, including the hypothalamic-pituitary pathway, reproductive organs, pituitary gland, and sex hormones. Progesterone plays an important role in the reproductive system of men and women, like pituitary glands and follicle stimulating hormones.
- Abnormal levels of progesterone are associated with increased follicle stimulating hormone, estrogen and progesterone levels. Increases in luteinizing hormone concentrations indicate menopause in women, polycystic ovary syndrome, and primary gonadotropin, and primary gonadotropin in men. Conversely, reduced concentrations of luteinizing hormone indicate primary hypergonadism.
- the hormone is gonadotropin releasing hormone (GnRH).
- the peptide comprising an amino acid sequence of SEQ ID NO: 1, an amino acid sequence having a sequence homology of 80% or more with SEQ ID NO: 1, or a fragment thereof may act as a gonadotropin releasing hormone analog, and gonadotropin releasing hormone analog Gonadotropin-releasing hormone may have an effect as an agonist or antagonist.
- the gonadotropin releasing hormone analogs are associated with steroid-related diseases (e.g., prostate cancer, breast cancer, and ovarian cancer), diseases associated with hypogonadal dysfunction (e.g. irregular menstruation, amenorrhea, precocious puberty, and hypogonadal function).
- Control of the ovulation cycle during fertilization e.g. ovulation cycle, which can be selectively controlled by administration of gonadotropin-releasing hormone agonists or antagonists
- contraception e.g. gonadotropin release after embryo growth and implantation rate May be inhibited and reduced by administration of hormone antagonists
- the potential use in the pharmaceutical field of the present invention can be made as a gonadotropin releasing hormone analog, and can be used to regulate gonadotropin releasing hormone effect, and such gonadotropin releasing hormone effect regulation is the effect of gonadotropin releasing hormone effect.
- Enhancement or reduction for example by controlling such effects 1) anti-cancer treatment of hormone-sensitive cancers such as prostate cancer or breast cancer; 2) treatment of estrogen production disturbances in women, including menstrual hyperplasia, endometriosis, uterine fibroids, and fibroids of the uterus; 3) infertility of women and men and 4) treatment of child precocious puberty, and 5) treatment and improvement of prostate hyperplasia.
- GnRH gonadotropin releasing hormone
- Another aspect of the present invention provides a composition for controlling hormone secretion comprising a hormone secretion regulator according to the present invention.
- Another aspect of the present invention provides a pharmaceutical composition for controlling hormone secretion, comprising a hormone secretion regulator and a pharmaceutically acceptable additive according to the present invention.
- Another aspect of the present invention provides a pharmaceutical composition for controlling gonadotropin releasing hormone effect comprising the gonadotropin releasing hormone (GnRH) analogue according to the present invention.
- GnRH gonadotropin releasing hormone
- the composition of the invention is 0.1 mg / mg to 1 mg / mg, specifically 1 ⁇ g / mg to 0.5 mg / mg, more specifically 10 ⁇ g / mg of 0.1 mg / mg , Peptides consisting of the amino acids of SEQ ID NO: 1, or amino acids having at least 80% homology with SEQ ID NO: 1, or fragments of the foregoing.
- the peptide is included in the above range, all the safety and stability of the composition is appropriate and satisfied in terms of cost-efficiency.
- compositions of the invention can be administered to all animals, including humans, dogs, chickens, pigs, cattle, sheep, guinea pigs or monkeys.
- the pharmaceutical composition of the present invention as an active ingredient, a peptide consisting of amino acids of SEQ ID NO: 1, a peptide having at least 80% homology with a peptide of SEQ ID NO: 1 or a fragment peptide of SEQ ID NO: 1 do.
- the pharmaceutical composition of the present invention can be administered orally, rectally, transdermal, intravenous, intramuscular, intraperitoneal, intramedullary, intradural or subcutaneous.
- Hormone secretion modulator may act as the gonadotropin-releasing hormone analog, the pharmaceutical composition comprising the same, as described in the present invention, the progress of the hormone level or disease or condition causing the pathological symptoms It is especially useful for the treatment of subjects (human or otherwise) with illnesses or symptoms related to the hormone levels that have been affected. Therefore, the pharmaceutical composition according to the present invention can be used for the treatment, amelioration or prevention of diseases caused by excessive or lack of hormones, especially sex hormones.
- the disease caused by an excess or deficiency of the hormone is prostate cancer, breast cancer, ovarian cancer, hypermenorrhea (menorrhagia), endometriosis, endometriosis, adenomyosis, uterine fibroids, women Or male or male infertility, precocious puberty in children, enlarged prostate, and combinations thereof, but is not limited thereto.
- the pharmaceutical composition may be formulated in conventional pharmaceutical formulations known in the art.
- the medicament may be formulated and administered in any formulation including, but not limited to, oral, injectable, suppository, transdermal, and non-administrative formulations, but preferably, may be formulated in a formulation for oral administration. .
- Formulations for oral administration may be, but are not limited to, tablets, pills, soft or hard capsules, granules, powders, solutions or emulsions.
- Formulations for parenteral administration may be, but are not limited to, administrations, drops, lotions, ointments, gels, creams, suspensions, emulsions, suppositories, patches or sprays.
- the pharmaceutical composition may include additives such as diluents, excipients, lubricants, binders, disintegrants, buffers, dispersants, surfactants, colorants, flavoring or sweetening agents as necessary.
- additives such as diluents, excipients, lubricants, binders, disintegrants, buffers, dispersants, surfactants, colorants, flavoring or sweetening agents as necessary.
- Pharmaceutical compositions according to one aspect of the invention may be prepared by conventional methods in the art.
- the active ingredient of the pharmaceutical composition may vary greatly depending on the age, sex, weight, condition and condition of the patient, the method of administration, the judgment of the prescriber.
- Specific dosage determinations are within the level of those skilled in the art, and their daily dosage may be, for example, specifically 0.1 ⁇ g / kg / day to 1 g / kg / day, more specifically 1 ⁇ g / kg / day to 10 mg / kg / day, more specifically 10 ⁇ g / kg / day to 1 mg / kg / day, even more specifically 50 ⁇ g / kg / day to 100 ⁇ g / kg / day.
- administration of the pharmaceutical composition is not limited thereto, and may be 1 to 3 times a day.
- the food composition may include a peptide consisting of amino acids of SEQ ID NO: 1 as an active ingredient, amino acids having at least 80% homology with SEQ ID NO: 1, or fragments of the foregoing.
- the food composition is not limited to form, and may be, for example, granules, powders, liquids, and solids.
- Each form can typically be mixed with ingredients suitably selected by those skilled in the art, and can also be added to the active ingredient, and the effect can be enhanced by mixing with other ingredients.
- the daily dosage of the food composition is within the level of one skilled in the art, the daily dosage of which is for example specifically 0.1 ⁇ g / kg / day to 1 g / kg / day, more specifically 1 ⁇ g / kg / May be from 1 to 10 mg / kg / day, more specifically from 10 ⁇ g / kg / day to 1 mg / kg / day, even more specifically from 50 ⁇ g / kg / day to 100 ⁇ g / kg / day,
- the present invention is not limited thereto and may vary depending on various factors such as age, health condition, and complications of the subject to be administered.
- the peptides according to the invention can be administered in combination with an adjuvant.
- the composition, pharmaceutical composition, and food composition according to the present invention may include an adjuvant.
- adjuvants may include any immunological adjuvant known in the art, including, for example, inorganic adjuvants such as aluminum salts, and organic adjuvants such as oils, virosomes, squalanes, and the like. It includes.
- Organic adjuvants include, but are not limited to, emulsions, microbe-derived, synthetic adjuvants, cytokines, and the like. 9 kinds of cytokine adjuvant are known.
- GM-CSF granulocyte-macrophage colony-stimulating factor
- Appropriate dosages of the adjuvant referred to herein are already well known in the art and can be administered according to criteria known in the art, depending on the condition of each patient. Specific dosage determinations are within the level of those skilled in the art, and their daily dosage may be, for example, specifically 1 ⁇ g / kg / day to 10 g / kg / day, more specifically 10 ⁇ g / kg / day to 100 mg / kg / day, and more specifically, 50 ⁇ g / kg / day to 10 mg / kg / day, but is not limited to this, depending on a variety of factors, such as age, health conditions, complications of the subject to be administered Can be.
- intradermal doses of 7 to 700 mg prior to administration of the peptides disclosed herein such as from 1 minute to 150 minutes before, 5 to 80 minutes before, or 10 to 15 minutes before May be administered.
- the administration time may be administered at least 1 minute before, at least 3 minutes, at least 5 minutes, at least 7 minutes, at least 8 minutes, at least 9 minutes or at least 10 minutes before the peptide administration.
- the dosage can be at least 7 mg, at least 10 mg, at least 20 mg, at least 30 mg, at least 40 mg, at least 50 mg, at least 60 mg or at least 70 mg.
- the dosage may be 700 mg or less, 600 mg or less, 500 mg or less, 400 mg or less, 300 mg or less, 200 mg or less, 100 mg or less, 90 mg or less, or 80 mg or less.
- composition according to the present invention provides a kit for controlling hormone secretion comprising instructions.
- the instructions may include the active ingredient, content, properties, efficacy effect, dosage, storage method, period of use, seller, manufacturer, date of manufacture, side effects, and / or contraindications of the pharmaceutical composition according to the present invention.
- Another aspect of the present invention provides a use of the hormone secretion modulator according to the present invention for preparing a medicament for controlling hormone secretion.
- Another aspect of the present invention provides a method for controlling hormone levels comprising administering an effective amount of a hormone secretion modulator according to the present invention to a subject in need thereof.
- Another aspect of the present invention provides a method for regulating hormone levels comprising administering an effective amount to the subject in need of hormone regulation treatment, the hormone composition for controlling hormone secretion according to the present invention.
- hormone level control method can be applied as described for the horbon secretion regulator and the pharmaceutical composition according to the present invention.
- the method for controlling hormone levels includes increasing or decreasing hormone levels for reaching a steady state or for treating, improving, or preventing a hormone-induced disease, which depends on the type of disease caused by the hormone. Can vary.
- the target hormone of the hormone level control method is testosterone (testosterone), estrogen (estrogen), follicle stimulating hormone (FSH, follicle stimulating hormone), luteinizing hormone (LH, luteinizing hormone), gonadotropin releasing hormone (GnRH, Gonadotropin- releasing hormone), and combinations thereof.
- the hormone level control method may be appropriately determined by those skilled in the art, and in one embodiment, a method of administering the pharmaceutical composition may be applied.
- the hormone secretion regulator or hormone secretion pharmaceutical composition can be administered once a day.
- the method of level regulation can treat, ameliorate or prevent diseases caused by excess or deficiency of hormones, in particular sex hormones.
- the disease caused by an excess or deficiency of the hormone is prostate cancer, breast cancer, ovarian cancer, hypermenorrhea (menorrhagia), endometriosis, endometriosis, adenomyosis, uterine fibroids, women Or male or male infertility, precocious puberty in children, enlarged prostate, and combinations thereof, but is not limited thereto.
- Another aspect of the present invention provides the use of the gonadotropin releasing hormone analogue according to the present invention for producing a medicament for controlling gonadotropin releasing hormone effect.
- Another aspect of the present invention provides a method for controlling gonadotropin releasing hormone effect comprising administering an effective amount of the gonadotropin releasing hormone analog according to the present invention to a subject in need of hormonal modulating therapy.
- the method for controlling the gonadotropin releasing hormone effect includes enhancing or decreasing the gonadotropin releasing hormone effect for reaching a steady state or for treating, improving, or preventing a disease caused by a hormone. It may vary depending on the type of disease caused.
- the gonadotropin releasing hormone analog or a pharmaceutical composition comprising the analog can be administered once a day.
- the gonadotropin releasing hormone effect control method can treat, ameliorate or prevent a disease caused by excess or deficiency of sex hormones.
- the disease caused by an excess or deficiency of the hormone is prostate cancer, breast cancer, ovarian cancer, hypermenorrhea (menorrhagia), endometriosis, endometriosis, adenomyosis, uterine fibroids, women Or male or male infertility, precocious puberty in children, enlarged prostate, and combinations thereof, but is not limited thereto.
- Preferred embodiments of the invention include the most optimal mode known to the inventors for carrying out the invention. Variations of the preferred embodiments may become apparent to those skilled in the art upon reading the foregoing description. The inventors expect those skilled in the art to make appropriate use of such variations, and the inventors expect the invention to be practiced in a manner different from that described herein. Accordingly, the invention includes all modifications and equivalents of the subject matter referred to in the appended claims, as permitted by patent law. Moreover, any combination of the abovementioned elements within all possible variations is included in the invention unless expressly stated to the contrary or apparently contradictory in context. While the invention has been particularly shown and described with reference to exemplary embodiments, those skilled in the art will understand that various changes in form and detail may be made without departing from the spirit and scope of the invention as defined by the following claims. will be.
- the present invention is a gonadotropin releasing hormone analog in the pharmaceutical field, 1) anti-cancer treatment of hormone-sensitive cancers such as prostate cancer or breast cancer, 2) hypermenstrual, endometriosis, uterine fibroids, uterine fibrocystic disturbances in women, etc. It can be used in the treatment of, 3) treatment of infertility of women and men, 4) treatment of precocious puberty in children, and 5) treatment and improvement of prostate hyperplasia.
- 1 is a graph showing the control loop of hormones including testosterone, estrogen, follicle stimulating hormone, luteinizing hormone and gonadotropin releasing hormone in male and female reproductive organs.
- Figure 2 is a graph showing the change in the concentration of testosterone in the blood of male rats repeatedly administered PEP-1 over time.
- Figure 3 is a graph showing the change in the concentration of testosterone in the blood of female rats repeatedly administered PEP-1 over time.
- Figure 4 is a graph showing the change in the concentration of estradiol E2 in the blood of male rats repeatedly administered PEP-1 over time.
- 5 is a graph showing the change in the concentration of estradiol E2 in the blood of female rats repeatedly administered PEP-1 over time.
- Figure 6 is a graph showing the change in follicle stimulating hormone concentration in the blood of male rats repeatedly administered PEP-1 over time.
- FIG. 7 is a graph showing the change in follicle stimulating hormone concentration in the blood of female rats repeatedly administered PEP-1 over time.
- 9 is a graph showing the change in the concentration of luteinizing hormone in the blood of female rats repeatedly administered PEP-1 over time.
- 10 and 11 are graphs showing the relative mRNA expression levels of gonadotropin-releasing hormone in male and female rats after administration of PEP-1.
- FIG. 12 is a graph showing the degree of cell proliferation in the parenchymal cell line (WPMY-1) of an enlarged prostate animal model treated with PEP-1 (GV1001).
- FIG. 13 is a graph showing the extent of cell proliferation in epithelial cell line (RWPE-1) of an enlarged prostate animal model treated with PEP-1 (GV1001).
- a peptide comprising SEQ ID NO: 1, a peptide having at least 80% sequence homology with the peptide sequence, or a fragment thereof, was prepared according to a conventional solid phase peptide synthesis method. Specifically, peptides were synthesized by coupling amino acids one by one from the C-terminus through Fmoc solid phase synthesis (SPPS) using ASP48S (Peptron, Inc., Daejeon, Korea). As follows, the first amino acid at the C-terminus of the peptides was attached to the resin. For example:
- Coupling reagent is HBTU [2- (1H-Benzotriazole-1-yl) -1,1,3,3-tetamethylaminium hexafluorophosphate] / HOBt [N-Hydroxxybenzotriazole] / NMM [4-Methylmorpholine] It was. Fmoc removal was performed using piperidine in DMF in 20% of DMF.
- Each peptide was synthesized by repeating a process of reacting the amino acids with each other, washing with a solvent, and then deprotecting the amino acid using the state in which the amino acid protecting group was bound to the solid support.
- the synthesized peptide was separated from the resin and then purified by HPLC, and confirmed by MS and lyophilized.
- Pep 1 (EARPALLTSRLRFIPK) consisting of SEQ ID NO: 1, the specific process is as follows.
- PEP-1 (peptide of SEQ ID NO: 1) is lyophilized according to the method described in Example 1, taking into account the correction factor of PEP-1 (purity: 94.13%, content: 92.36%, correction factor: 1.15) What was obtained in the form of white powder was dissolved in 0.9% saline.
- the 50 mg / mL stock solution was also diluted with 0.9% saline at 20 mg / mL, 2 mg / mL, and 1 mg / mL, respectively, and stored for one week before being used at 4 ° C.
- the purpose of this example was to identify changes in sex hormones in blood, and was performed in SD rats that were repeatedly administered the peptide of SEQ ID NO: 1, PEP-1 daily for 7 days.
- This experiment was conducted by KAMSI Inc.
- the animal testing regulations specified by the Korea Animal Medical Science Institue were followed.
- this experiment is a Non-GLP experiment, which is directed by the Ministry of Food and Drug Safety (MFDS); See Agent 2013-40 (April 5, 2013), Principles of Good Laboratory Practice (1997).
- SPF mice (Crlj: CD (SD) were obtained from ORIENTBio Inc. (Mokdong-ri, Buk-myeon, Gapyeong-gun, Gyeonggi-do, Korea). 75 males (6.5 weeks, 190-210 g) and 75 females (6.5 weeks, 160-180 g) were observed for 4 days, and 64 males and females were selected as experimental subjects. Growth conditions are as follows: temperature of 23 ⁇ 3 ° C., relative humidity of 5 ⁇ 15%, air exchange of 10-20 times / hour, roughness 150-300 lux intensity of 12 hours (8 am to 8 pm) Of hours.
- the environment of the animal facility for example temperature-humidity, the number of air exchanges, and the intensity of light were measured regularly.
- Animal food produced by Cargill Agri Purina. Inc.
- DreamBios Co., Ltd (507, 507, Gwangnaru-ro, Gwangjin-gu, Seoul, Korea).
- Purified water was given using a polycarbonate bottle, and the bedding of the rat kennel was made by SaeronBio Inc. (800-17, Cheonggye-dong, Uiwang-si, Gyeonggi-do, Korea).
- Dosage regimens include, for example, the drug, route, dosage, volume, etc .:
- the detailed dosing regimens are as follows: once daily, twice daily and twice weekly in each experimental group. Dosing began at 10 am daily and each rat was administered at 1 minute intervals each. Mice in groups 9, 10, 13, and 14 were administered twice a week. Administration of high doses preceded administration of low doses. The volume of dosing was calculated using the most recently measured rat weight, which is 5 mL / kg. Subcutaneous administration was performed as follows: When the assistant held the rat's back upwards, the experimenter disinfected the rat's back with 70% alcohol and the test drug was administered subcutaneously using a 26G syringe.
- 1.4 mL of blood sample (0.7 mL of serum) was collected after weighing (Day 0). The following day (Day 1), 1.4 mL of blood sample (0.7 mL of serum) was collected twice after administration of test drug (4 and 8 hours after test drug administration, respectively). Six days later (Day 2-Day 7), 1.4 mL of blood was collected once daily (4 hours after test drug administration). The dose and volume of the test drug were as shown in Table 3, respectively, and the administration time slot was also performed at the same time every day. Blood was extracted from the jugular vein and stored at room temperature for 30 minutes. Serum was separated by centrifuge (10,000 rpm per 5 minutes) and stored until just before use in a deep freezer at -70 ⁇ 5 ° C. Blood collection was done in each subject at the same time every day.
- CLIA Chemi-Luminescence Immune Assay
- Testosterone was analyzed using the sample prepared in Example 2. 15 ⁇ L of serum was used for the analysis. The basis of the assay is a competitive immunoassay, based on direct chemi-fluorescence. As mentioned in Example 2, a CLIA kit was used for testosterone analysis, following the manufacturer's protocol. The results are as follows: Testosterone levels in all groups before injection of PEP-1 or vehicle were 1-3 ng / dL. On the first day, testosterone levels increased in all groups except the group injected with vehicle up to 6-10 ng / dL. On the second day, testosterone levels were highest in the G3, G5, G11, and G15 groups, which were administered once daily infusion therapy.
- testosterone levels decreased and there was no significant difference between the groups injected with PEP-1 and vehicle and returned to normal levels.
- the baseline of testosterone was too low to find anything unusual.
- the female group had testosterone levels below 0.2 ng / dL prior to PEP-1 or vehicle infusion, continued to drop to 0.05 ng / dL after infusion of PEP-1, and returned to normal levels on day 3. come. According to this, it is believed that PEP-1 has no obvious effect on testosterone levels in female rats (see Table 4 and Figures 2 and 3).
- Estradiol E2 was analyzed using the sample prepared in Example 2. 75 ⁇ L of serum was used for the analysis. The basis of the assay is a competitive immunoassay, based on direct chemi-fluorescence. As mentioned in Example 2, CLIA kits were used for analysis, following the manufacturer's protocol. In the male group, the average blood level of estradiol E2 was lower than that of females, and the initial level of estradiol E2 (prior to infusion of PEP-1) was maintained at day 15-20 pg / mL until PEP-1 was estradiol. It did not affect the level of E2.
- estradiol E2 decreased from 20-50 pg / mL (baseline) to 16-30 pg / mL in all PEP1 groups in the right group. These levels remained constant until day 3, and from day 4 the levels of estradiol E2 increased to 40-50 pg / mL in the G4, G10 and vehicle groups, then returned to normal levels (Table 5 and Figure 4). , 5).
- PEP-1 initially inhibited the estradiol E2 levels in the female group, but recovered from day 3-4, especially as the number of infusions and the dose of test drug were associated with the inhibition of estradiol E2 levels. Seemed.
- Follicle stimulating hormone was analyzed using the sample prepared in Example 2. 100 ⁇ L of serum was used for the analysis. The basis of the assay is a two-site sandwich immunoassay, based on direct chemi-fluorescence. As mentioned in Example 2, CLIA kits were used for analysis and followed manufacturer's protocol.
- Example 2 LH was analyzed using the sample prepared in Example 2. 50 ⁇ L of serum was used for the analysis. The basis of the assay is a two-site sandwich immunoassay, based on direct chemi-fluorescence. As mentioned in Example 2, CLIA kits were used for analysis, following the manufacturer's protocol.
- PEP-1 appeared to promote luteinizing hormone secretion in both males and females, and increased levels of luteinizing hormones, especially at high doses and frequent infusions.
- the luteinizing hormone levels in male rats were 0.1 mIU / mL before PEP-1 administration and increased to 0.5-1.5 mIU / mL after 4 hours in all groups except vehicle.
- Levels of luteinizing hormone were highest in G5, G11, and G15 where daily dosing regimens were administered. After 8 hours, the levels of progesterone decreased rapidly and remained normal until termination.
- luteinizing hormone levels also increased after 4 hours, but did not increase much from the G12, G14, and G16 groups of the high dose regimen. In addition, after 8 hours, luteinizing hormone levels returned to normal levels (see Table 7 and Figures 8 and 9).
- Spargue-Dawley rats obtained from Orient Bio (Gyeonggi-do, Korea) were used for the study at 7 weeks of age. Mice were divided into four groups (G1-G4) and are shown in Table 8. Mice receive 2 (1st and 7th) infusions of PEP-1 (100 mg / kg) subcutaneously for 7 days of study. Blood samples (1.4 mL) were collected on Day 0 (prior to administration of PEP-1), Day 1 (after 4 and 8 hours after injection), and Day 7 (after 4 hours of injection). Serum samples were obtained from blood and used for the experiment. Serum samples were collected from blood collected on day 1 (4 hours after injection) and used for the experiment. Treatment and progression of animals was approved in accordance with the provisions of KAMSI's IACUC.
- RNA isolation and cDNA synthesis were performed from serum samples.
- miRNeasy Serum / Plasma Spike-In Control was added to each serum sample before RNA extraction, total RNA was extracted and purified from the serum sample, and the miRNeasy Serum / Plasma Kit (Qiagen, Valencia, CA, USA). ) And the manufacturer's instructions.
- the first-strand of the cDNA sample was synthesized from total RNAs using a Reverse Transcription System (Promega, Madison, Wisconsin).
- Rat serum samples obtained from blood samples 4 hours after injection of PEP-1 (100 mg / kg) on Day 1 were used for the analysis of mRNA expression of gonadotropin-releasing hormone. 10 and 11, in both male and female rats, relative gonadotropin releasing hormone mRNA expression was increased by administration of PEP-1.
- An increase in gonadotropin-releasing hormone levels is observed in serum samples, which is associated with an initial spike in luteinizing hormone and follicle stimulating hormone after 4 hours of the first injection, shown in Figures 6-9.
- the results show up-regulation of gonadotropin releasing hormone mRNA levels of PEP-1, which supports the possibility of PEP-1 pharmacologic application as gonadotropin releasing hormone agonists or analogues. .
- the sex hormone modulator of the present invention is effective in controlling sex hormones including testosterone, estrogen, follicle stimulating hormone, luteinizing hormone and gonadotropin releasing hormone.
- Testosterone when injected into the body, becomes a form of dehydrotestosterone (DHT) due to 5 ⁇ -reductase, which promotes prostate cell proliferation, which causes prostatic hyperplasia (BPH).
- DHT dehydrotestosterone
- BPH prostatic hyperplasia
- PEP-1 (GV1001) administration experiments on the proliferation inhibitory effect of prostate cell lines were performed as follows. Cell lines were obtained from the prostatic parenchymal cell line (WPMY-1) and epithelial cell line (RWPE-1) obtained from an enlarged prostate animal model.
- the sex hormone modulators of the present invention are effective for the treatment, improvement or prevention of diseases caused by hormonal excess or deficiency such as prostate hyperplasia.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Endocrinology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Diabetes (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Reproductive Health (AREA)
- Wood Science & Technology (AREA)
- Mycology (AREA)
- General Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Toxicology (AREA)
- Gynecology & Obstetrics (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Pregnancy & Childbirth (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
Description
본 명세서의 일 측면에서, 서열의 상동성은 종래에 알려진 하기의 방법들로 결정되었다. Smith and Waterman, 1981, Adv. Appl. Math. 2:482, by the search for similarity method of Pearson & Lipman, 1988, Proc. Natl. Acad. Sci. USA 85:2444, using the CLUSTAL W algorithm of Thompson et al., 1994, Nucleic Acids Res 22:467380, by computerized implementations of these algorithms (GAP, BESTFIT, FASTA, and TFASTA in the Wisconsin Genetics Software Package, Genetics Computer Group). The BLAST algorithm (Altschul et al., 1990, Mol. Biol. 215:403-10) for which software may be obtained through the National Center for Biotechnology Information (www.ncbi.nlm.nih.gov/) may also be used. When using any of the aforementioned algorithms, the default parameters for "Window" length, gap penalty, etc.
테스토스테론은 체내에 주입되면 5α-reductase로 인해 DHT (dehydrotestosterone)의 형태가 되어 전립선 세포 증식을 촉진하고 이로 인해 전립선 비대증 (BPH)을 유발한다. 이 사실에 기초하여 다음과 같이 전립선 세포주의 세포 증식 억제효과에 대한 PEP-1 (GV1001) 투여 실험이 진행 되었다. 세포주는 전립선 비대 동물모델에서 얻은 전립선의 실질 세포주 (WPMY-1)와 상피 세포주 (RWPE-1)를 사용하였다. 실험방법은 WPMY-1 (2.5х103 cells)와 RWPE-1 (1х104 cells)를 96 well에 시딩 (seeding) 하고, 표 10 과 같은 실험군을 대상으로 증식 변화를 확인하였다. 증식 변화 확인은 배양액 흡입 (suction) 후, CCK-8 solution을 각 well에 10 L씩 넣어준 후, 1-4 hr동안 450 nm로 광학 밀도 (optical density)를 측정하는 방식으로 진행하였다.
Claims (29)
- 서열번호 1의 아미노산 서열, 서열번호 1과 80% 이상의 서열 상동성을 갖는 아미노산 서열, 또는 이들의 단편를 포함하는 펩티드를 포함하는 호르몬 분비 조절제.
- 제1항에 있어서, 상기 호르몬은 테스토스테론 (testosterone), 에스트로겐(estrogen), 여포자극호르몬(FSH, follicle stimulating hormone), 황체형성호르몬(LH, luteinizing hormone), 성선자극호르몬 방출호르몬(GnRH, Gonadotropin-releasing hormone), 및 이들의 조합으로 이루어진 군에서 선택되는 것인 호르몬 분비 조절제.
- 제2항에 있어서, 상기 에스트로겐은 에스트론(estrone), 에스트라디올(estradiol) 또는 에스트리올(estriol)인 호르몬 분비 조절제.
- 제2항에 있어서, 상기 호르몬은 성선자극호르몬 방출호르몬(GnRH, Gonadotropin-releasing hormone)인 호르몬 분비 조절제.
- 제1항 내지 제4항 중 어느 한 항에 따른 호르몬 분비 조절제를 포함하는 호르몬 분비 조절용 조성물.
- 제1항 내지 제4항 중 어느 한 항에 따른 호르몬 조절제 및 약학적으로 허용 가능한 첨가제를 포함하는 호르몬 분비 조절용 약학 조성물.
- 제6항에 있어서, 상기 조성물은 어쥬번트(adjuvant)를 더 포함하는 것인 약학 조성물.
- 제7항에 있어서, 상기 어쥬번트는 그래뉼로사이트-마크로파지 콜로니-자극 인자(granulocyte-macrophage colony-stimulating factor, GM-CSF)인 약학 조성물.
- 제6항에 있어서, 상기 조성물은 호르몬의 과다 또는 결핍에 의한 질환의 치료, 개선 또는 예방을 위한 것인 약학 조성물.
- 제9항에 있어서, 상기 질환은 전립선암, 유방암, 난소암, 월경과다증(menorrhagia), 자궁내막증(endometriosis), 자궁선근종증(adenomyosis), 자궁섬유양(uterine fibroids), 여성 또는 남성 불임(female or male infertility), 소아 성조숙증(precocious puberty in children), 전립선 비대증, 및 이들의 조합으로 이루어진 군에서 선택되는 것인 약학 조성물.
- 호르몬 분비 조절용 의약을 제조하기 위한 제1항 내지 제4항 중 어느 한 항에 따른 호르몬 분비 조절제의 사용.
- 제11항에 있어서, 상기 호르몬 분비 조절은 호르몬의 과다 또는 결핍에 의한 질환의 치료, 개선 또는 예방을 위한 것인 사용.
- 제12항에 있어서, 상기 질환은 전립선암, 유방암, 난소암, 월경과다증(menorrhagia), 자궁내막증(endometriosis), 자궁선근종증(adenomyosis), 자궁섬유양(uterine fibroids), 여성 또는 남성 불임(female or male infertility), 소아 성조숙증(precocious puberty in children), 전립선 비대증, 및 이들의 조합으로 이루어진 군에서 선택되는 것인 사용.
- 제6항 내지 제10항 중 어느 한 항에 따른 약학 조성물; 및설명서를 포함하는 호르몬 분비 조절용 키트.
- 제1항 내지 제4항 중 어느 한 항에 따른 호르몬 분비 조절제를, 호르몬 조절 치료를 필요로 하는 대상에게 유효한 양을 투여하는 것을 포함하는 호르몬 레벨 조절 방법.
- 제6항 내지 제10항 중 어느 한 항에 따른 호르몬 분비 조절용 약학 조성물을, 호르몬 조절 치료를 필요로 하는 대상에게 유효한 양을 투여하는 것을 포함하는 호르몬 레벨 조절 방법.
- 제15항 또는 제16항에 있어서, 1일 1회 투여하는 것인 호르몬 레벨 조절 방법.
- 제15항 또는 제16항에 있어서, 상기 호르몬이 테스토스테론 (testosterone), 에스트로겐(estrogen), 여포자극호르몬(FSH, follicle stimulating hormone), 황체형성호르몬(LH, luteinizing hormone), 성선자극호르몬 방출호르몬(GnRH, Gonadotropin-releasing hormone)으로 이루어진 군에서 선택되는 하나 이상인 호르몬 레벨 조절 방법.
- 서열번호 1의 아미노산 서열, 서열번호 1과 80% 이상의 서열 상동성을 갖는 아미노산 서열, 또는 이들의 단편을 포함하는 펩티드를 포함하는 성선자극호르몬 방출호르몬(GnRH) 아날로그.
- 제19항에 있어서, 성선자극호르몬 방출호르몬(GnRH) 아날로그는 GnRH 아고니스트(agonist) 또는 안타고니스트(antagonist)인 성선자극호르몬 방출호르몬 아날로그.
- 제19항 또는 제20항에 따른 성선자극호르몬 방출호르몬 아날로그의 유효한 양을 호르몬 조절 치료를 필요로 하는 대상에게 투여하는 것을 포함하는 성선자극호르몬 방출 호르몬 효과 조절 방법.
- 제19항 또는 제20항에 따른 성선자극호르몬 방출호르몬 아날로그를 포함하는 성선자극호르몬 방출 호르몬 효과 조절용 약학 조성물.
- 제22항에 있어서, 약학적으로 허용가능한 첨가제를 더 포함하는 것인 약학 조성물.
- 제22항에 있어서, 상기 조성물은 어쥬번트를 더 포함하는 것인 약학 조성물.
- 제22항 내지 제24항 중 어느 한 항에 있어서, 상기 조성물은 성선 호르몬의 과다 또는 결핍에 의한 질환의 치료 또는 예방을 위한 것인 약학 조성물
- 제25항에 있어서, 상기 질환은 전립선암, 유방암, 난소암월경과다증(menorrhagia), 자궁내막증(endometriosis), 자궁선근종증(adenomyosis), 자궁섬유양(uterine fibroids), 여성 또는 남성 불임(female or male infertility), 소아 성조숙증(precocious puberty in children), 전립선 비대증, 및 이들의 조합으로 이루어진 군에서 선택되는 것인 약학 조성물.
- 성선자극호르몬 방출 호르몬 효과 조절용 의약을 제조하기 위한 제19항 또는 제20항에 따른 성선자극호르몬 방출호르몬 아날로그의 사용.
- 제27항에 있어서, 상기 성선자극호르몬 방출 호르몬 효과 조절은 호르몬의 과다 또는 결핍에 의한 질환의 치료, 개선 또는 예방을 위한 것인 사용.
- 제28항에 있어서, 상기 질환은 전립선암, 유방암, 난소암, 월경과다증(menorrhagia), 자궁내막증(endometriosis), 자궁선근종증(adenomyosis), 자궁섬유양(uterine fibroids), 여성 또는 남성 불임(female or male infertility), 소아 성조숙증(precocious puberty in children), 전립선 비대증, 및 이들의 조합으로 이루어진 군에서 선택되는 것인 사용.
Priority Applications (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
ES14814647T ES2808076T3 (es) | 2013-06-21 | 2014-06-23 | Regulador de la secreción hormonal, composición que lo contiene y procedimiento para controlar la secreción hormonal mediante su uso |
EP14814647.5A EP3011967B1 (en) | 2013-06-21 | 2014-06-23 | Hormone secretion regulator, composition containing same, and method for controlling hormone secretion using same |
JP2016521216A JP6495899B2 (ja) | 2013-06-21 | 2014-06-23 | ホルモン分泌調節剤、及びそれを含む組成物 |
KR1020157034623A KR20160039152A (ko) | 2013-06-21 | 2014-06-23 | 호르몬 분비 조절제, 이를 포함하는 조성물, 및 이를 사용한 호르몬 분비 조절 방법 |
KR1020197005889A KR102166545B1 (ko) | 2013-06-21 | 2014-06-23 | 호르몬 분비 조절제, 이를 포함하는 조성물, 및 이를 사용한 호르몬 분비 조절 방법 |
CN201480034361.6A CN105324123B (zh) | 2013-06-21 | 2014-06-23 | 激素分泌调节剂、包含该调节剂的组合物、和利用其控制激素分泌的方法 |
US14/899,746 US10561703B2 (en) | 2013-06-21 | 2014-06-23 | Method of modulating sex hormone levels using a sex hormone secretion modulator |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP13173219.0 | 2013-06-21 | ||
EP13173219 | 2013-06-21 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2014204281A1 WO2014204281A1 (ko) | 2014-12-24 |
WO2014204281A9 true WO2014204281A9 (ko) | 2015-03-12 |
Family
ID=48672449
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/KR2014/005508 WO2014204281A1 (ko) | 2013-06-21 | 2014-06-23 | 호르몬 분비 조절제, 이를 포함하는 조성물, 및 이를 사용한 호르몬 분비 조절 방법 |
Country Status (8)
Country | Link |
---|---|
US (1) | US10561703B2 (ko) |
EP (1) | EP3011967B1 (ko) |
JP (1) | JP6495899B2 (ko) |
KR (2) | KR20160039152A (ko) |
CN (1) | CN105324123B (ko) |
ES (1) | ES2808076T3 (ko) |
TW (1) | TWI539960B (ko) |
WO (1) | WO2014204281A1 (ko) |
Families Citing this family (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3428181A3 (en) | 2012-05-11 | 2019-02-20 | KAEL-GemVax Co., Ltd. | Anti-inflammatory peptides and composition comprising the same |
CN104507489B (zh) | 2012-05-11 | 2016-07-13 | 杰姆维克斯&凯尔有限公司 | 用于预防和治疗类风湿性关节炎的组合物 |
EP2873678B8 (en) | 2012-07-11 | 2024-07-17 | Gemvax & Kael Co., Ltd. | Conjugate comprising a cell-penetrating peptide and compositions comprising same |
KR102258864B1 (ko) | 2013-04-19 | 2021-06-01 | 주식회사 젬백스앤카엘 | 허혈성 손상 치료 및 예방용 조성물 |
JP6059405B2 (ja) | 2013-06-07 | 2017-01-11 | ジェムバックス アンド カエル カンパニー,リミティド | 癌の免疫学的治療に有用な生物学的マーカー |
KR102166544B1 (ko) * | 2013-10-23 | 2020-10-16 | 주식회사 젬백스앤카엘 | 전립선 비대증 치료 및 예방용 조성물 |
WO2015076621A1 (ko) | 2013-11-22 | 2015-05-28 | 주식회사 카엘젬백스 | 혈관 신생 억제 활성을 가지는 펩티드 및 이를 포함하는 조성물 |
EP3085380B1 (en) * | 2013-12-17 | 2020-06-17 | Gemvax & Kael Co., Ltd. | Composition for treating prostate cancer |
KR102373603B1 (ko) | 2014-04-11 | 2022-03-14 | 주식회사 젬백스앤카엘 | 섬유증 억제 활성을 가지는 펩티드 및 이를 포함하는 조성물 |
ES2962532T3 (es) | 2014-04-30 | 2024-03-19 | Gemvax & Kael Co Ltd | Composición para el trasplante de órganos, tejidos o células, kit y procedimiento de trasplante |
KR102413243B1 (ko) | 2014-12-23 | 2022-06-27 | 주식회사 젬백스앤카엘 | 안질환 치료 펩티드 및 이를 포함하는 안질환 치료용 조성물 |
CN107405380B (zh) | 2015-02-27 | 2021-04-20 | 珍白斯凯尔有限公司 | 用于预防听觉损伤的肽及其包含该肽的组合物 |
KR102423955B1 (ko) * | 2015-04-24 | 2022-07-22 | 주식회사 젬백스앤카엘 | 발기부전 치료 활성을 가지는 펩티드 및 이를 포함하는 조성물 |
KR102638286B1 (ko) | 2015-07-02 | 2024-02-20 | 주식회사 젬백스앤카엘 | 항바이러스 활성 효능을 가지는 펩티드 및 이를 포함하는 조성물 |
WO2017176087A1 (ko) | 2016-04-07 | 2017-10-12 | 주식회사 젬백스앤카엘 | 텔로머라제 활성 증가 및 텔로미어 연장 효능을 가지는 펩티드 및 이를 포함하는 조성물 |
KR102118953B1 (ko) * | 2018-01-19 | 2020-06-04 | 전남대학교산학협력단 | 골손실의 완화, 치료 또는 예방용 약학조성물 및 건강기능식품 |
CN110801512B (zh) * | 2019-11-15 | 2023-07-18 | 中国水产科学研究院黑龙江水产研究所 | 一种用于促进哲罗鲑性腺成熟的多肽及其应用 |
Family Cites Families (77)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
HU207799B (en) | 1991-07-24 | 1993-06-28 | Beres Export Import Rt | Process for producing pharmaceutical composition for influencing the reticuloendothelial system, for treating chronic pain symptomes of degenerative locomotor disorders or tumors, and for treating mucoviscidosis |
JP2000515523A (ja) | 1996-07-22 | 2000-11-21 | ザ・ビクトリア・ユニバーシティ・オブ・マンチェスター | 創傷および線維性障害の治療における性ステロイド機能モジュレーターの使用 |
US6610839B1 (en) | 1997-08-14 | 2003-08-26 | Geron Corporation | Promoter for telomerase reverse transcriptase |
ATE361099T1 (de) | 1997-05-15 | 2007-05-15 | Chugai Pharmaceutical Co Ltd | Heilmittel für kachexie |
EP0917579A1 (en) | 1997-07-01 | 1999-05-26 | Cambia Biosystems LLC | Vertebrate telomerase genes and proteins and uses thereof |
US7030211B1 (en) * | 1998-07-08 | 2006-04-18 | Gemvax As | Antigenic peptides derived from telomerase |
US6378526B1 (en) | 1998-08-03 | 2002-04-30 | Insite Vision, Incorporated | Methods of ophthalmic administration |
IL132406A0 (en) | 1998-10-21 | 2001-03-19 | Pfizer Prod Inc | Treatment of bph with cgmp elevators |
US6815426B2 (en) | 2001-02-16 | 2004-11-09 | E. I. Du Pont De Nemours And Company | Angiogenesis-inhibitory tripeptides, compositions and their methods of use |
RU2282446C2 (ru) | 2001-04-10 | 2006-08-27 | Ниппон Синяку Ко., Лтд. | Лекарственное средство для хронического суставного ревматизма |
DK1425028T3 (da) | 2001-05-16 | 2010-03-01 | Yeda Res & Dev | Anvendelse af IL-18 inhibitorer til behandling eller forebyggelse af sepsis |
US20030143228A1 (en) | 2001-10-29 | 2003-07-31 | Baylor College Of Medicine | Human telomerase reverse transcriptase as a class-II restricted tumor-associated antigen |
US7786084B2 (en) | 2001-12-21 | 2010-08-31 | Biotempt B.V. | Treatment of burns |
PL372928A1 (en) | 2002-04-10 | 2005-08-08 | Applied Research Systems Ars Holding N.V. | Use of osteoprotegerin for the treatment and/or prevention of fibrotic disease |
KR20050020987A (ko) | 2002-06-12 | 2005-03-04 | 바이오겐 아이덱 엠에이 인코포레이티드 | 아데노신 수용체 길항제를 사용하여 허혈 재관류 손상을치료하는 방법 |
US20080025986A1 (en) | 2003-06-06 | 2008-01-31 | Ozes Osman N | Methods of Treating Tnf-Mediated Disorders |
JP4705567B2 (ja) | 2003-06-25 | 2011-06-22 | 株式会社 キャンバス | 免疫調整活性、抗炎症活性、および抗ウイルス活性を有するペプチドおよびペプチド模倣物 |
KR20050040517A (ko) | 2003-10-29 | 2005-05-03 | 주식회사 오리엔트 | 허혈성 질환에 대한 저항성을 나타내는 형질전환 생쥐 |
DE60303854T2 (de) | 2003-11-11 | 2006-08-10 | Mattern, Udo | Nasenformulierung mit kontrollierter Freisetzung von Sexualhormonen |
GB0426146D0 (en) | 2004-11-29 | 2004-12-29 | Bioxell Spa | Therapeutic peptides and method |
CA2646131C (en) | 2005-03-21 | 2018-09-04 | Vicus Therapeutics Spe 1, Llc | Compositions and methods for ameliorating cachexia |
KR20080084818A (ko) | 2005-11-25 | 2008-09-19 | 각고호우징 게이오기주크 | 전립선암 치료제 |
AU2006325030B2 (en) | 2005-12-16 | 2012-07-26 | Cellectis | Cell penetrating peptide conjugates for delivering nucleic acids into cells |
WO2007097561A1 (en) | 2006-02-20 | 2007-08-30 | Ewha University - Industry Collaboration Foundation | Peptide having cell membrane penetrating activity |
CN101490080A (zh) | 2006-07-24 | 2009-07-22 | 为人技术株式会社 | 用于缓解和治疗缺血性病症的药物组合物及其输送方法 |
CA2676797C (en) | 2007-01-29 | 2014-04-22 | Dae Woong Jo | Novel macromolecule transduction domains and methods for identification and uses thereof |
MY150234A (en) | 2007-06-29 | 2013-12-31 | Ahn Gook Pharmaceutical Company Ltd | Predictive markers for ovarian cancer |
MX2010001684A (es) | 2007-08-15 | 2010-04-21 | Amunix Inc | Composiciones y metodos para modificar propiedades de polipeptidos biologicamente activos. |
WO2009046739A1 (en) * | 2007-10-09 | 2009-04-16 | Curevac Gmbh | Composition for treating prostate cancer (pca) |
WO2009054996A2 (en) | 2007-10-25 | 2009-04-30 | Genelux Corporation | Systems and methods for viral therapy |
GB2455539B (en) | 2007-12-12 | 2012-01-18 | Cambridge Entpr Ltd | Anti-inflammatory compositions and combinations |
WO2010003520A2 (en) * | 2008-06-16 | 2010-01-14 | Genovax S.R.L. | Anti-tumor immunotherapy |
ES2334315B1 (es) | 2008-07-29 | 2011-02-28 | Universitat Pompeu Fabra | Peptidos con capacidad de penetracion celular y sus usos. |
US20110183925A1 (en) | 2008-09-22 | 2011-07-28 | Nisshin Pharma Inc. | Anti-inflammatory peptide |
KR101169030B1 (ko) | 2009-01-21 | 2012-07-26 | 애니젠 주식회사 | 신규한 세포막 투과 도메인 및 이를 포함하는 세포내 전달 시스템 |
EP2428211A4 (en) | 2009-05-07 | 2013-04-03 | Moon & J Inc | PHARMACEUTICAL COMPOSITION FOR THE PREVENTION OR TREATMENT OF NEURAL DAMAGE AND NEUROLOGICAL DISEASES |
EP2251028A1 (en) | 2009-05-12 | 2010-11-17 | Biocompatibles Uk Ltd. | Treatment of eye diseases using encapsulated cells encoding and secreting an anti-angiogenic factor and/or a neuroprotective factor |
US7928067B2 (en) | 2009-05-14 | 2011-04-19 | Ischemix Llc | Compositions and methods for treating ischemia and ischemia-reperfusion injury |
BRPI1008230B1 (pt) | 2009-05-20 | 2019-05-28 | Toray Industries, Inc. | Peptídeo de penetração celular e composição farmacêutica |
KR20110057049A (ko) | 2009-11-23 | 2011-05-31 | 박의신 | 기능성 전립선염 치료제 |
KR20110062943A (ko) | 2009-12-04 | 2011-06-10 | 주식회사종근당 | 퀴나졸린 유도체를 유효성분으로 하는 전립선 비대증 예방 또는 치료제 |
ES2664866T3 (es) | 2010-01-11 | 2018-04-23 | Curna, Inc. | Tratamiento de enfermedades relacionadas con la globulina fijadora de hormonas sexuales (shbg) mediante inhibición del transcrito antisentido natural a shbg |
EP2536830B1 (en) * | 2010-02-16 | 2019-07-17 | Ultimovacs AS | Polypeptides |
FR2960542B1 (fr) | 2010-05-27 | 2012-08-17 | Esther Suzy Arlette Fellous | Peptide en tant que medicament, en particulier pour le traitement du cancer |
KR101263212B1 (ko) | 2010-05-28 | 2013-05-10 | 성신여자대학교 산학협력단 | 신규한 세포막 투과성 펩타이드 및 그의 용도 |
WO2011150493A1 (en) | 2010-05-30 | 2011-12-08 | The Governing Council Of The University Of Toronto | Mitochondrial penetrating peptides as carriers for antimicrobials |
WO2011155803A2 (ko) | 2010-06-11 | 2011-12-15 | 아주대학교산학협력단 | 청각보호 작용을 하는 신규 화합물 |
KR101348284B1 (ko) | 2010-09-09 | 2014-01-03 | 주식회사 나이벡 | 인간 유래 세포 투과성 펩타이드와 생리활성 펩타이드 결합체 및 그 용도 |
US20120208755A1 (en) | 2011-02-16 | 2012-08-16 | Intarcia Therapeutics, Inc. | Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers |
KR20120121196A (ko) | 2011-04-26 | 2012-11-05 | 주식회사 글루칸 | 관절염 치료제 |
KR101284772B1 (ko) | 2011-05-24 | 2013-07-17 | 정종문 | 항염증, 진통효과를 가지는 기능성 식품 조성물 |
KR20120133661A (ko) | 2011-05-31 | 2012-12-11 | 주식회사 바이오포트코리아 | 아스타잔틴을 포함하는 항염증제 |
KR101288053B1 (ko) | 2011-07-04 | 2013-07-23 | 동국대학교 산학협력단 | 필발 추출물을 유효성분으로 포함하는 내이손상 예방 및 치료용 조성물 |
KR101361445B1 (ko) | 2011-12-26 | 2014-02-12 | 성균관대학교산학협력단 | 펩타이드, 5-플루오로우라실, 및 성숙수지상세포를 포함하는 암 치료용 약학적 조성물 |
DE13746292T1 (de) | 2012-02-10 | 2014-10-30 | Hakushinkouseikai Foundation | Proliferationsmittel für monozyten, kulturmedium zur proliferation von monozyten, verfahren zur herstellung von monozyten, verfahren zur herstellung dendritischer zellen und verfahren zur herstellung eines impfstoffs mit dendritischen zellen |
KR102041381B1 (ko) | 2012-03-12 | 2019-11-27 | 젬백스 에이에스 | 능동적인 면역치료법을 이용한 비-소세포성 폐암의 치료 |
CN104507489B (zh) * | 2012-05-11 | 2016-07-13 | 杰姆维克斯&凯尔有限公司 | 用于预防和治疗类风湿性关节炎的组合物 |
EP3428181A3 (en) | 2012-05-11 | 2019-02-20 | KAEL-GemVax Co., Ltd. | Anti-inflammatory peptides and composition comprising the same |
EP2873678B8 (en) | 2012-07-11 | 2024-07-17 | Gemvax & Kael Co., Ltd. | Conjugate comprising a cell-penetrating peptide and compositions comprising same |
US20150125438A1 (en) | 2012-07-20 | 2015-05-07 | Sang Jae Kim | Anti-Inflammatory Peptides and Composition Comprising the Same |
KR102038487B1 (ko) | 2012-09-19 | 2019-10-30 | 주식회사 젬백스앤카엘 | 텔로머라제 펩티드를 포함하는 항균 또는 항진균용 조성물 |
KR102578890B1 (ko) | 2012-09-19 | 2023-09-18 | 주식회사 젬백스앤카엘 | 세포 투과성 펩티드, 그를 포함한 컨쥬게이트 및 그를 포함한 조성물 |
US9631184B2 (en) | 2012-09-19 | 2017-04-25 | Gemvax & Kael Co., Ltd. | Cell penetrating peptide, conjugate comprising same, and composition comprising conjugate |
ES2758451T3 (es) | 2012-09-19 | 2020-05-05 | Gemvax & Kael Co Ltd | Péptido de penetración celular, conjugado que comprende el mismo y composición que comprende el conjugado |
PT2897620T (pt) | 2012-09-21 | 2020-09-03 | Intensity Therapeutics Inc | Método de tratamento de cancro |
KR102258864B1 (ko) | 2013-04-19 | 2021-06-01 | 주식회사 젬백스앤카엘 | 허혈성 손상 치료 및 예방용 조성물 |
TWI634210B (zh) * | 2013-05-03 | 2018-09-01 | 傑姆維克斯&凱爾有限公司 | 抑制熱休克蛋白質表現之胜肽及包含其之組成物 |
JP6059405B2 (ja) | 2013-06-07 | 2017-01-11 | ジェムバックス アンド カエル カンパニー,リミティド | 癌の免疫学的治療に有用な生物学的マーカー |
KR102166544B1 (ko) | 2013-10-23 | 2020-10-16 | 주식회사 젬백스앤카엘 | 전립선 비대증 치료 및 예방용 조성물 |
WO2015076621A1 (ko) | 2013-11-22 | 2015-05-28 | 주식회사 카엘젬백스 | 혈관 신생 억제 활성을 가지는 펩티드 및 이를 포함하는 조성물 |
EP3085380B1 (en) | 2013-12-17 | 2020-06-17 | Gemvax & Kael Co., Ltd. | Composition for treating prostate cancer |
KR102373603B1 (ko) | 2014-04-11 | 2022-03-14 | 주식회사 젬백스앤카엘 | 섬유증 억제 활성을 가지는 펩티드 및 이를 포함하는 조성물 |
ES2962532T3 (es) | 2014-04-30 | 2024-03-19 | Gemvax & Kael Co Ltd | Composición para el trasplante de órganos, tejidos o células, kit y procedimiento de trasplante |
KR102413243B1 (ko) | 2014-12-23 | 2022-06-27 | 주식회사 젬백스앤카엘 | 안질환 치료 펩티드 및 이를 포함하는 안질환 치료용 조성물 |
CN107405380B (zh) | 2015-02-27 | 2021-04-20 | 珍白斯凯尔有限公司 | 用于预防听觉损伤的肽及其包含该肽的组合物 |
EP3372613A4 (en) | 2015-11-03 | 2019-07-10 | Gemvax & Kael Co., Ltd. | PEPTIDE WITH NERVE DAMAGE PREVENTION AND REGENERATION EFFECT AND COMPOSITION THEREOF |
KR20170054310A (ko) | 2015-11-09 | 2017-05-17 | 주식회사 젬백스앤카엘 | 텔로머라제 유래 펩티드를 포함하는 수지상세포 치료제 및 면역 치료제, 및 이를 사용하는 치료방법 |
-
2014
- 2014-06-23 EP EP14814647.5A patent/EP3011967B1/en active Active
- 2014-06-23 KR KR1020157034623A patent/KR20160039152A/ko active Search and Examination
- 2014-06-23 US US14/899,746 patent/US10561703B2/en active Active
- 2014-06-23 ES ES14814647T patent/ES2808076T3/es active Active
- 2014-06-23 JP JP2016521216A patent/JP6495899B2/ja active Active
- 2014-06-23 CN CN201480034361.6A patent/CN105324123B/zh active Active
- 2014-06-23 TW TW103121483A patent/TWI539960B/zh active
- 2014-06-23 KR KR1020197005889A patent/KR102166545B1/ko active IP Right Grant
- 2014-06-23 WO PCT/KR2014/005508 patent/WO2014204281A1/ko active Application Filing
Also Published As
Publication number | Publication date |
---|---|
KR102166545B1 (ko) | 2020-10-16 |
JP2016523248A (ja) | 2016-08-08 |
KR20190025744A (ko) | 2019-03-11 |
KR20160039152A (ko) | 2016-04-08 |
CN105324123A (zh) | 2016-02-10 |
US10561703B2 (en) | 2020-02-18 |
TWI539960B (zh) | 2016-07-01 |
EP3011967B1 (en) | 2020-06-17 |
EP3011967A4 (en) | 2017-03-29 |
CN105324123B (zh) | 2022-02-08 |
WO2014204281A1 (ko) | 2014-12-24 |
TW201505648A (zh) | 2015-02-16 |
EP3011967A1 (en) | 2016-04-27 |
JP6495899B2 (ja) | 2019-04-03 |
US20160137695A1 (en) | 2016-05-19 |
ES2808076T3 (es) | 2021-02-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2014204281A9 (ko) | 호르몬 분비 조절제, 이를 포함하는 조성물, 및 이를 사용한 호르몬 분비 조절 방법 | |
WO2015060673A1 (ko) | 전립선 비대증 치료 및 예방용 조성물 | |
Harvey et al. | Autocrine/paracrine roles of extrapituitary growth hormone and prolactin in health and disease: An overview | |
Samuel et al. | The effect of relaxin on collagen metabolism in the nonpregnant rat pubic symphysis: the influence of estrogen and progesterone in regulating relaxin activity | |
WO2013169077A1 (ko) | 악액질 예방 또는 치료용 조성물 | |
WO2015093854A1 (ko) | 전립선 암 치료용 조성물 | |
EP0593491B1 (en) | Luteinizing hormone releasing hormone antagonist peptides | |
Li | Hormones of the adenohypophysis | |
US4338305A (en) | Use of LRH and LRH agonists | |
Tomooka et al. | Growth of mouse mammary glands after neonatal sex hormone treatment | |
Schwärzler et al. | Prolactin gene expression and prolactin protein in premenopausal and postmenopausal human ovaries | |
WO2015111832A1 (ko) | 지실 추출물을 포함하는 전립선 관련 질환의 예방 또는 치료용 조성물 | |
WO2018074682A1 (ko) | 항비만 및 항당뇨 효능을 갖는 펩타이드 및 이의 용도 | |
Chaube et al. | Kisspeptins stimulate the hypothalamus-pituitary-ovarian axis and induce final oocyte maturation and ovulation in female stinging catfish (Heteropneustes fossilis): Evidence from in vivo and in vitro studies | |
Liu et al. | Channel catfish follicle-stimulating hormone and luteinizing hormone: complementary DNA cloning and expression during ovulation | |
Rosen et al. | Local regulation within the female reproductive system and upon embryonic implantation: identification of cells expressing proenkephalin A | |
WO2021251790A1 (ko) | 항비만 활성을 가지는 디옥시콜산-펩타이드 결합체 및 이의 용도 | |
WO2016144125A2 (ko) | 용규 추출물의 신규 용도 | |
Wadia et al. | Effect of the human follicle-stimulating hormone-binding inhibitor and its N-terminal fragment on follicle-stimulating hormone-induced progesterone secretion by granulosa cells in vitro | |
Huang et al. | Elevated expression of inhibin α gene in sterile allotriploid crucian carp | |
Sheth et al. | Potential application of inhibin in male and female contraception | |
Moodbidri et al. | Inhibin: unity in diversity | |
CN116003573A (zh) | 一种***β亚基活性肽及其应用 | |
Espey | Overview Oncologic, Endocrine & Metabolic: Female contraception: novel methods and developments | |
KR100210472B1 (ko) | 황체형성 호르몬 분비 호르몬 길항 펩티드 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 201480034361.6 Country of ref document: CN |
|
ENP | Entry into the national phase |
Ref document number: 20157034623 Country of ref document: KR Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2014814647 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 14899746 Country of ref document: US |
|
ENP | Entry into the national phase |
Ref document number: 2016521216 Country of ref document: JP Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 14814647 Country of ref document: EP Kind code of ref document: A1 |